Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>Revenue reached JPY89.1bn (+18.3% YoY), with domestic business at JPY80.0bn (+20.9% YoY) and China business at JPY9.1bn (-0.8% YoY).</li><li>Operating profit increased 106.4% YoY to JPY21.1bn, with a cost of revenue ratio decline of 5.8pp to 48.5%.</li><li>Prescription Kampo formulations revenue was JPY77.1bn (+21.0% YoY), with a 21.6% drug price increase from April 2024 revision.</li></ul>

Revenue reached JPY89.1bn (+18.3% YoY), with domestic business at JPY80.0bn (+20.9% YoY) and China business at JPY9.1bn (-0.8% YoY).Operating profit increased 106.4% YoY to JPY21.1bn, with a cost of revenue ratio decline of 5.8pp to 48.5%.Prescription Kampo formulations revenue was JPY77.1bn (+21.0% YoY), with a 21.6% drug price increase from April 2024 revision.

Tsumura & Co (4540 JP): 1H FY03/25 flash update

<ul><li>Revenue: JPY43.7bn (+18.0% YoY), Operating profit: JPY10.6bn (+125.8% YoY), Recurring profit: JPY14.1bn (+135.7% YoY), Net Income: JPY11.2bn (+158.1% YoY).</li><li>Domestic business revenue: JPY40.1bn (+21.7% YoY), China business revenue: JPY3.6bn (-12.1% YoY), Prescription Kampo formulations revenue: JPY38.8bn (+21.9% YoY).</li><li>Cost of revenue ratio decreased by 7.2pp to 47.7%, SG&A expense ratio decreased by 4.3pp to 28.1%, driven by higher sales.</li></ul>

Revenue: JPY43.7bn (+18.0% YoY), Operating profit: JPY10.6bn (+125.8% YoY), Recurring profit: JPY14.1bn (+135.7% YoY), Net Income: JPY11.2bn (+158.1% YoY).Domestic business revenue: JPY40.1bn (+21.7% YoY), China business revenue: JPY3.6bn (-12.1% YoY), Prescription Kampo formulations revenue: JPY38.8bn (+21.9% YoY).Cost of revenue ratio decreased by 7.2pp to 47.7%, SG&A expense ratio decreased by 4.3pp to 28.1%, driven by higher sales.

Tsumura & Co (4540 JP): Q1 FY03/25 flash update

Japan

TSUMURA & CO. manufactures and sells pharmaceutical products including Chinese medicines.  The Company also manufactures and sells bathing products, cosmetics, and other healthcare and toiletry products.  Tsumura & Co. sells its products in Japan and overseas markets.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Tsumura & Co (4540 JP)